Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Berbamine is a bisbenzylisoquinoline alkaloid isolated from plants such as Cocculus orbiculatus. It is classified as a small molecule and has been studied for its potential pharmacological activities including anti-tumor effects (notably in KRAS-mutant lung adenocarcinoma), calcium channel blocking activity (inhibiting calcium-induced contraction of smooth muscle), and possible neuroprotective properties. Mechanistically, it acts as a calcium channel blocker and has been shown to modulate the STING pathway in cancer cells by downregulating p-STING (Ser366) and CCL2 expression. This leads to reduced infiltration of myeloid-derived suppressor cells into the tumor microenvironment and enhances anti-tumor immunity. Berbamine also exhibits pro-apoptotic effects by triggering cell cycle arrest and promoting cellular senescence in cancer models[7][8][10]. It is considered investigational with ongoing research into its therapeutic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on berbamine.